Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ESBRIET vs ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Pirfenidone inhibits TGF-β stimulated collagen production and reduces fibroblast proliferation, exhibiting anti-inflammatory and antifibrotic effects in pulmonary fibrosis.
Isolyte E in Dextrose 5% provides fluid, electrolytes, and calories. Dextrose is metabolized to carbon dioxide and water, yielding energy. Electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) maintain acid-base balance and osmotic pressure.
Idiopathic pulmonary fibrosis (IPF)
FDA-approved: For intravenous administration as a source of water, electrolytes, and calories in patients requiring fluid and electrolyte replacement.,Off-label: Not typically used off-label; primarily for maintenance or replacement therapy.
801 mg three times daily orally with food.
Intravenous infusion; typical adult dose is 1000-2000 m L per day (30 m L/kg/day) adjusted for fluid and electrolyte needs; rate based on clinical status.
Terminal elimination half-life is approximately 3 hours (range 1.5-5 hours) in healthy adults. In patients with idiopathic pulmonary fibrosis, half-life is similar but exhibits interindividual variability.
Not applicable; components are endogenous substances. Dextrose half-life ~15-20 min after infusion; electrolytes distribute and are cleared renally with half-lives dependent on renal function.
Primarily hepatic via CYP1A2 (major), with minor contributions from CYP2C9, CYP2C19, CYP2D6, and CYP2E1.
Dextrose undergoes glycolysis and the citric acid cycle; electrolytes are not metabolized but are excreted or incorporated into body pools.
Renal excretion of parent drug and metabolites accounts for approximately 99% of elimination, with about 82% recovered in urine and 1% in feces. Pirfenidone is extensively metabolized, with less than 1% excreted unchanged.
ISOLYTE E in Dextrose 5% is a balanced electrolyte solution with glucose. Electrolytes are primarily excreted renally; water and dextrose are metabolized. Biliary/fecal excretion is negligible. Dextrose is metabolized to CO2 and water.
Protein binding is approximately 50-58%, primarily to albumin.
None for electrolytes and dextrose; sodium, potassium, chloride, magnesium, acetate, and gluconate are free ions in solution.
Volume of distribution is approximately 1.0 L/kg, indicating extensive tissue distribution.
Sodium and chloride distribute primarily in extracellular fluid (~0.2 L/kg). Dextrose distributes in total body water (~0.6 L/kg). Potassium distributes in intracellular fluid (~0.6 L/kg after equilibration).
Oral bioavailability is approximately 80% (range 70-90%) under fed conditions; food reduces peak concentration but increases total exposure.
100% intravenous; not administered by other routes.
GFR 30-50 m L/min: 267 mg three times daily; GFR < 30 m L/min: not recommended.
In renal impairment (e GFR < 30 m L/min/1.73m²), reduce total volume to 500-1000 m L/day with careful monitoring of potassium, sodium, and glucose; avoid if hyperkalemia or fluid overload.
Child-Pugh A: 801 mg three times daily; Child-Pugh B: 267 mg three times daily; Child-Pugh C: contraindicated.
No specific dose adjustment for Child-Pugh class; monitor for fluid overload and electrolyte imbalances; in severe hepatic impairment, reduce volume to 500-1000 m L/day.
Not established; safety and efficacy in pediatric patients have not been studied.
Weight-based: 20-50 m L/kg/day for maintenance; neonates and infants: 100-150 m L/kg/day; adjust based on glucose, electrolytes, and hydration status; maximum rate 4 m L/kg/hour for neonates.
No specific dose adjustment recommended; monitor renal function and consider lower starting dose due to age-related decline in renal function.
Start with lower volumes (500-1000 m L/day) due to decreased renal function and risk of fluid overload; monitor serum electrolytes, glucose, and central venous pressure.
None
Not applicable; no FDA boxed warning exists for this product.
Hepatotoxicity: monitor liver function tests before and during treatment; discontinue if significant elevation.,Photosensitivity and rash: avoid sun exposure; use sunscreen.,Gastrointestinal effects: nausea, diarrhea, dyspepsia; take with food.,Elevated liver enzymes: dose reduction or interruption may be required.
Monitor serum electrolytes, fluid balance, and glucose levels; avoid fluid overload in patients with cardiac or renal impairment; risk of hyperglycemia in diabetic patients; use with caution in patients with metabolic alkalosis or hypokalemia.
Severe hepatic impairment (Child-Pugh Class C),Severe renal impairment requiring dialysis,History of hypersensitivity to pirfenidone or any excipient
Hypersensitivity to any component; clinically significant hyperglycemia; severe metabolic acidosis; hyperkalemia (for potassium-containing formulations); hypermagnesemia; fluid overload conditions.
Take with meals to reduce GI intolerance. Grapefruit and grapefruit juice may increase pirfenidone blood levels and should be avoided. Avoid smoking as it induces CYP1A2 and may reduce drug efficacy.
No specific food interactions known. Monitor electrolyte intake in patients with electrolyte imbalances.
Pirfenidone is teratogenic in animal studies, causing fetal malformations and embryotoxicity at clinically relevant exposures. There are no adequate human studies. Use during pregnancy is contraindicated; effective contraception is required before and during treatment. First trimester carries the highest risk for major congenital anomalies; second and third trimester risks include fetal growth restriction and potential pulmonary toxicity.
ISOLYTE E in Dextrose 5% is an intravenous electrolyte and carbohydrate solution. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. Dextrose and electrolytes are considered essential nutrients and are generally safe when used as indicated. However, administration during labor and delivery may cause fluid and electrolyte imbalances. First trimester risks are theoretical; second and third trimesters may involve risks of maternal hyperglycemia and fetal hyperinsulinemia if dextrose infusion is excessive. No specific teratogenicity reported.
No human data on milk excretion; animal studies show drug and metabolites present in breast milk. Unknown M/P ratio. Risk of infant toxicity cannot be excluded. Breastfeeding is not recommended during therapy and for 2 weeks after last dose.
Dextrose and electrolytes are normal constituents of human milk. Following intravenous administration, concentrations in milk are expected to parallel maternal plasma levels. No specific M/P ratio is available. Use during breastfeeding is considered compatible; however, monitor for adverse effects in the infant such as electrolyte imbalance or hyperglycemia if maternal infusion is prolonged or high volume.
No established dosing guidelines for pregnancy. Significant pharmacokinetic changes (increased volume of distribution, renal clearance) may reduce drug exposure. Theoretical adjustments are not recommended due to unknown safety; therapy should be discontinued if pregnancy occurs. If continuation is deemed unavoidable, dose individualization based on therapeutic drug monitoring is suggested but unvalidated.
Pregnancy induces increased plasma volume and glomerular filtration rate, potentially diluting electrolytes and altering glucose metabolism. Dose adjustments may be required: consider lower dextrose infusion rates to avoid maternal hyperglycemia and fetal hyperinsulinemia. Monitor electrolytes closely; adjust potassium and magnesium supplementation as needed. No specific dose adjustment is universally recommended; individualize based on maternal weight, clinical status, and monitoring results.
Pirfenidone (Esbriet) is an antifibrotic agent approved for idiopathic pulmonary fibrosis (IPF). It reduces decline in lung function but does not reverse fibrosis. Monitor liver function tests (LFTs) monthly for 6 months then every 3 months due to risk of hepatotoxicity. Photosensitivity is common; advise strict sun avoidance and broad-spectrum sunscreen. Dosage titration over 14 days reduces GI side effects. Avoid use with strong CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin) as they increase pirfenidone exposure.
ISOLYTE E in DEXTROSE 5% is an isotonic crystalloid solution for IV administration. Contains electrolytes (Na, K, Mg, Cl, acetate, gluconate) and dextrose 5%. Use with caution in patients with renal impairment, heart failure, or hyperkalemia. Monitor serum electrolytes, blood glucose, and fluid balance. Not for use as a sole source of nutrition. Do not administer if solution is discolored or contains particulates.
Take with food to reduce nausea and upset stomach.,Avoid sun exposure; wear protective clothing and apply sunscreen daily due to risk of severe sunburn.,Do not stop or change dose without consulting your doctor; taper is not required but missed doses should be skipped.,Report any signs of liver problems: yellowing of skin/eyes, dark urine, fatigue, or abdominal pain.,Avoid smoking and grapefruit products as they may affect drug levels.
Inform your healthcare provider about all medical conditions, especially kidney disease, heart failure, or diabetes.,Report any signs of allergic reaction such as rash, itching, or trouble breathing.,Tell your doctor if you experience swelling, shortness of breath, or irregular heartbeat.,This solution contains dextrose (sugar); monitor blood glucose if you have diabetes.,Do not use if the bag is damaged or solution is cloudy.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ESBRIET vs ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
ESBRIET is a Antifibrotic that works by Pirfenidone inhibits TGF-β stimulated collagen production and reduces fibroblast proliferation, exhibiting anti-inflammatory and antifibrotic effects in pulmonary fibrosis.. ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution with Dextrose that works by Isolyte E in Dextrose 5% provides fluid, electrolytes, and calories. Dextrose is metabolized to carbon dioxide and water, yielding energy. Electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) maintain acid-base balance and osmotic pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ESBRIET and ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ESBRIET is: 801 mg three times daily orally with food.. The standard adult dose of ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; typical adult dose is 1000-2000 m L per day (30 m L/kg/day) adjusted for fluid and electrolyte needs; rate based on clinical status.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ESBRIET and ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ESBRIET is classified as Category C. Pirfenidone is teratogenic in animal studies, causing fetal malformations and embryotoxicity at clinically relevant exposures. There are no adequate human studies. Use during pregn. ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. ISOLYTE E in Dextrose 5% is an intravenous electrolyte and carbohydrate solution. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies h. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.